Abdelkader Hamdi Battah

Abdelkader Hamdi Battah

University of Jordan

H-index: 13

Asia-Jordan

Professor Information

University

University of Jordan

Position

Professor of Toxicology Faculty of Medicine the

Citations(all)

697

Citations(since 2020)

267

Cited By

546

hIndex(all)

13

hIndex(since 2020)

9

i10Index(all)

19

i10Index(since 2020)

8

Email

University Profile Page

University of Jordan

Research & Interests List

Toxicology

Clinical Toxicology

Forensic Toxicology

Top articles of Abdelkader Hamdi Battah

Illicit drug use among medical students and its association with gender, psychological distress sleep quality and exposure to psychiatry: a nationwide study

PurposeIllicit drug use is a well-known global problem that has been noticed to be increased significantly among medical students. This study aims to assess the prevalence and consequences of illicit drug use among medical students in the country of Jordan using the validated Drug Abuse Screening Test-10 (DAST-10).Design/methodology/approachThe authors used a cross-sectional, descriptive design to conduct this study. A total of 2,104 participants from six medical schools were included. A structured online-based English self-administered questionnaire was used for data collection.FindingsOut of 2,104 included participants, 242 (11.5%) reported using illicit drugs in the past year. More than three-quarters (77%) of the drug users suffer from various degrees of problems related to drug use, ranging from risky (41%) to severe risk (6%). Drug use was found to be associated with gender, planned specialty and …

Authors

Rayan M Joudeh,Raba’a F Jarrar,Adnan Raed Alnaser,Abdelkader Battah,Mazen Hindi,Arwa A Battah,Eslam M Wadi,Osama A Zitoun

Journal

Mental Health Review Journal

Published Date

2024/2/1

Effect of dysnatremia and dysglycemia on outcomes among surgical intensive care unit patients

Objectives:The objectives of this study were to evaluate the relationships between serum sodium and glucose concentrations and outcomes among patients admitted to the surgical intensive care unit.Materials and Methods:Patient records admitted to the surgical intensive care unit (SICU) between July 2020 and December 2020 were used in the study. Data included in the analysis were patient age, gender, comorbidities, surgical intervention, diagnosis of sepsis, sequential organ system failure scores, serum sodium concentrations, serum glucose concentrations, and surgical intensive care unit outcomes (discharged vs. deceased). A univariate logistic regression analysis was used to determine significant risk factors for mortality during a surgical intensive care unit stay.Results:A total of 194 patients with a mean age of 60±16 years were admitted to the SICU during the study period. Twenty-three percent of the …

Authors

Mahmoud Abu Abeeleh,Hanan Hamouri,Amjad Bani Hani,Fatima M Ahmad,Sami Abu Halaweh,Wedad A Al-Warafi,Leen B Al Sahile,Zain M Abu Amrieh,Farah Abu Abeeleh,Abdelkader H Battah,Zuhair Bani Ismail,Saif Al Nassarwin,Tala Al Jaafreh,Mohammad Ribie,Mohammad Salameh,Anas HA Abu-Humaidan

Journal

International Journal of Surgery Open

Published Date

2024

General pattern of paediatric poisoning in Jordan during 2018–2019

IntroductionAcute accidental poisoning in children remains a significant public health issue and a predictable cause of morbidity around the world. To take preventive measures, it is necessary to identify the pattern of this problem.ObjectiveTo determine the extent and characteristics of paediatric poisoning, an epidemiological investigation specific to each country is required. The goal of our research was to determine the current pattern of acute poisoning in children between (0−5) years old in Jordan.MethodsThis retrospective study performs a descriptive analysis of the Jordan University Hospital’s National Poison Information Center (NPIC) database and describes the epidemiology of acute poisoning in children between (0−5) years old during a period of two years (2018–2019).ResultsPaediatric poisoning (0−5) years old accounts for approximately 88% of poisoning cases in Jordan between 2018 and 2019.Out of …

Authors

Layan M. Khraisat Enas M. ALzayadneh,Kamal A. ALHadidi,Ihab Alasasfeh,Abdelkader Battah,Suhad M. Khasawneh,Madeha N. Faouri,Robina W. Diab,Yaqin M. Alzagareet,Noourlhuda H. Abbas,Renad H. Al-Debei,Ayah M. Zaqqa,Farah K. Hadidi

Journal

Toxicology reports

Published Date

2024/3/21

Characterization of BCL-XL, MCL-1, and BAX Protein Expression in Response to Neoadjuvant Chemotherapy in Breast Cancer

The use of chemotherapy has improved the overall treatment of breast cancer, which is frequently administered in the form of neoadjuvant chemotherapy (NAC). Apoptosis is an established cell stress response to NAC in preclinical models; however, there is limited understanding of its role in clinical cancer, specifically, its contribution to favorable pathologic responses in breast cancer therapy. Here, we aimed to characterize the change in protein expression of 3 apoptosis-associated biomarkers, namely, BCL-X L, MCL-1, and BAX in breast cancer in response to NAC. For this, we utilized a set of 68 matched invasive breast cancer FFPE samples that were collected before (pre) and after (post) the exposure to NAC therapy that were characterized by incomplete pathologic response. Immunohistochemistry (IHC) analysis suggested that most of the samples show a decrease in the protein expression of all 3 markers …

Authors

Tareq Saleh,Sofian Al Shboul,Heyam Awad,Mohammed El-Sadoni,Ahmad Alhesa,Elham Alsharaiah,Nisreen Abu Shahin,Moureq R Alotaibi,AbdelKader Battah,Bilal Azab

Journal

Applied Immunohistochemistry & Molecular Morphology

Published Date

2024/3/1

Association of E23K (rs5219) polymorphism in the KCNJ11 gene with type 2 diabetes mellitus risk in Jordanian population

BackgroundThe E23K (rs5219) polymorphism in the potassium channel inward-rectifying subfamily J member 11 (KCNJ11) gene has been implicated with type 2 diabetes mellitus (T2DM) in several previous studies. However, contradictory findings observing a lack of association between this polymorphism and T2DM were also documented. For that reason, we investigated the E23K (rs5219) polymorphism relation to T2DM among Jordanians, analyzed its genotypic and allelic frequencies, and compared them with the findings among other populations.MethodsThe current study included 358 cases with T2DM and 326 controls without T2DM. The E23K (rs5219) polymorphism was genotyped using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique.ResultsAccording to our findings, The E23K (rs5219) polymorphism was associated with T2DM susceptibility in Jordanians …

Authors

Sawsan Al-Khalayfa,Safaa Mashal,Mariam Khanfar,Luma Srour,Lina Mustafa,Abdelkader Battah,Ayman A Zayed,Yousef S Khader,Bilal Azab

Journal

Human Gene

Published Date

2023/9/1

Investigating the utility of the SOFA score and creating a modified SOFA score for predicting mortality in the intensive care units in a tertiary Hospital in Jordan

Background. The utility of the Sequential Organ Failure Assessment (SOFA) score in predicting mortality in the intensive care unit (ICU) has been demonstrated before, but serial testing in various settings is required to validate and improve the score. This study examined the utility of the SOFA score in predicting mortality in Jordanian ICU patients and aimed to find a modified score that required fewer laboratory tests. Methods. A prospective observational study was conducted at Jordan University Hospital (JUH). All adult patients admitted to JUH ICUs between June and December 2020 were included in the study. SOFA scores were measured daily during the whole ICU stay. A modified SOFA score (mSOFA) was constructed from the available laboratory, clinical, and demographic data. The performance of the SOFA, mSOFA, qSOFA, and SIRS in predicting ICU mortality was assessed using the area under the receiver operating characteristic curve (AUROC). Results. 194 patients were followed up. SOFA score (mean ± SD) at admission was significantly higher in non-survivors (7.5 ± 3.9) compared to survivors (2.4 ± 2.2) and performed the best in predicting ICU mortality (AUROC = 0.8756, 95% CI: 0.8117–0.9395) compared to qSOFA (AUROC = 0.746, 95% CI: 0.655–0.836) and SIRS (AUROC = 0.533, 95% CI: 0.425–0.641). The constructed mSOFA included points for the hepatic and CNS SOFA scores, in addition to one point each for the presence of chronic kidney disease or the use of breathing support; it performed as well as the SOFA score in this cohort or better than the SOFA score in a subgroup of patients with heart disease …

Authors

Anas HA Abu-Humaidan,Fatima M Ahmad,Laith S Theeb,Abdelrahman J Sulieman,Abdelkader Battah,Amjad Bani Hani,Mahmoud Abu Abeeleh

Journal

Critical Care Research and Practice

Published Date

2023/8/7

Non-Dexamethasone Corticosteroid Therapy’s Effect on COVID-19 Prognosis in Cancer Patients: A Retrospective Study

Background Anti-inflammatory corticosteroids are used in cancer treatment and COVID-19 infections. Data on the impact of non-dexamethasone corticosteroids on COVID-19 infection severity in cancer patients are minimal. This study investigates if corticosteroid treatment affects the disease severity in adult cancer patients. Methods A total of 116 COVID-19-infected cancer patients on hydrocortisone (H) or prednisone (P) were compared to 343 untreated patients. The study included patients who received corticosteroids before (B), after (A), or both before and after (B and A) COVID-19 infections. Ventilation support, hospitalization and mortality were investigated. Results Our data showed that a significantly greater number of patients taking H or P required ventilation support and hospitalization and that mortality rates were higher than the control group. Patients who received H or P after COVID-19 infection had a significantly worse prognosis than the other sub-groups and the control group. Conclusion Corticosteroids impacted cancer patients’ COVID-19 prognosis. Despite the limited sample size, H- and P-treated patients’ corticosteroids performed worse than the control, especially if treatments were received after COVID-19 infection. Hence, when a cancer patient already on H or P treatment is diagnosed with COVID-19, we recommend switching to a steroid treatment as suggested by international guidelines.

Authors

Lina Souan,Zienab Al-Khairy,Abdelkader Battah,Maher A Sughayer

Journal

Vaccines

Published Date

2023/1/28

The Effect of Dexamethasone Treatment on COVID-19 Prognosis in Cancer Patients

Background Dexamethasone is used to treat cancer, relieve chemotherapy-induced nausea and vomiting, enhance cancer patients’ appetites, and treat COVID-19 patients. There is little evidence of the impact of a dexamethasone treatment plan on the severity of COVID-19 infections in cancer patients. This study explores whether dexamethasone treatment plan influences the severity of COVID-19 in dexamethasone-treated cancer patients. Methods The medical records of 108 cancer patients receiving dexamethasone at King Hussein Cancer Center with a COVID-19 infection and 343 without corticosteroid treatment were reviewed. Patients on dexamethasone within seven days before infection, after infection, or both were included. Ventilation support, hospitalization, and mortality within 28 days of a COVID-19 diagnosis were key severity factors. Results We found that dexamethasone before a COVID-19 infection increased the risk of requiring ventilation assistance and mortality within 28 days by a factor of 5.8 (2.8–12.0) relative to control (p < 0.005). Continuing dexamethasone treatment after a COVID-19 infection, or starting it after infection, had a risk factor equivalent to control. Conclusion Our data showed that dexamethasone therapy protocol affected COVID-19 prognoses in cancer patients, and it is preferable to not discontinue therapy after infection. A rigorous prospective comparison between early and late dexamethasone dosing is needed to determine the best protocol for treatment.

Authors

Lina Souan,Zienab Al-Khairy,Maysaa’Adnan Al-Binni,Abdelkader Battah,Maher A Sughayer

Journal

Vaccines

Published Date

2022/10/26

Professor FAQs

What is Abdelkader Hamdi Battah's h-index at University of Jordan?

The h-index of Abdelkader Hamdi Battah has been 9 since 2020 and 13 in total.

What are Abdelkader Hamdi Battah's research interests?

The research interests of Abdelkader Hamdi Battah are: Toxicology, Clinical Toxicology, Forensic Toxicology

What is Abdelkader Hamdi Battah's total number of citations?

Abdelkader Hamdi Battah has 697 citations in total.

What are the co-authors of Abdelkader Hamdi Battah?

The co-authors of Abdelkader Hamdi Battah are Fatma U Afifi, Talal Aburjai, Maha Shomaf, Yacoub Irshaid, Kamal A. Hadidi, Darwish H. Badran.

Co-Authors

H-index: 39
Fatma U Afifi

Fatma U Afifi

University of Jordan

H-index: 36
Talal  Aburjai

Talal Aburjai

University of Jordan

H-index: 18
Maha Shomaf

Maha Shomaf

University of Jordan

H-index: 18
Yacoub Irshaid

Yacoub Irshaid

University of Jordan

H-index: 16
Kamal A. Hadidi

Kamal A. Hadidi

University of Jordan

H-index: 16
Darwish H. Badran

Darwish H. Badran

University of Jordan

academic-engine

Useful Links